Clinical trials: Patients With Tumor
Sarcoma
CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin
This study evaluates the combination of CBT-1® and doxorubicin for the treatment of metastatic, unresectable sarcoma in patients who have progressed after treatment with 150mg/m2 or less of doxorubicin.
- Trial name
- NCT03002805
- Testing
- CBT-1®
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- CBA Research
Hepatocellular Carcinoma
Transarterial Chemoembolization Prior to Transplantation for Hepatocellular Carcinoma
The hope to treat more patients with hepatocellular carcinoma successfully is however tempered by the shortage of donors leading to an increasing waiting time for liver transplantation (LT).
- Trial name
- CATCH (NCT01676194)
- Testing
- Intra-arterial administration of DC BeadsR
- Where
- 7 sites in France
- Volunteers
- 7 people
- Sponsor
- Rennes University Hospital
Brain and Central Nervous System Tumors, Prostate Cancer
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by stopping blood flow to the tumor. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Trial name
- NCT00085566
- Testing
- everolimus, gefitinib
- Where
- 2 sites in United States, Spain
- Volunteers
- 61 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia
Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase I trial is studying the side effects and the best dose of alvocidib when given together with cyclophosphamide and rituximab in treating patients with high risk B-cell chronic lymphocytic leukemia or small lymphocytic…
- Conditions
- Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT01076556
- Testing
- Alvocidib Hydrochloride, Cyclophosphamide, Diagnostic Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Carcinoma
Clinical Data Collection in Studying Clinical Factors Associated With Post-Surgery Chronic Opioid Use in Patients With Head and Neck Cancers
This trial studies the risk of developing disorders associated with chronic opioid use post-surgery in patients with head and neck cancers.
- Trial name
- NCT03888651
- Testing
- Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Malignancies
This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.
This study is a first-in-human (FIH) study which is required to understand the safety, tolerability, pharmacokinetics and preliminary efficacy of RJK-RT2831 injection in patients with hematologic malignancies
- Trial name
- NCT06756451
- Testing
- RJK-RT2831 dose-escalation phase Ia, RJK-RT2831 Dose Expansion Phase Ib
- Where
- 16 sites in China
- Volunteers
- 71 people
- Sponsor
- Nanjing RegeneCore Biotech Co., Ltd.
Margins of Excision, Breast Cancer
Histolog Comparison to Standard Histology
This is a clinical device trial to assess the accuracy of margin assessment for a confocal scanning device (Histolog Scanner) at assessing the margins of breast tissue following wide local excision surgery.
- Trial name
- HiCoSH (NCT04857229)
- Testing
- Histolog Scanner
- Where
- United Kingdom
- Volunteers
- 101 people
- Sponsor
- Imperial College London
Prostate Cancer
The Physical Exercise and Prostate Cancer Study
The purpose of this study is to determine the effectiveness of a four months strength training program on physical and psychological health in patients with prostate cancer during androgen deprivation therapy.
- Trial name
- PEPC (NCT00658229)
- Testing
- Strength training group
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- Oslo University Hospital
Basal Cell Nevus Syndrome, Gorlin Syndrome
To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)
The purpose of this study is to reduce the number of new surgically eligible BCCs by 50% appearing during month 3-18 of medication ingestion.
- Trial name
- GDC-0449 (NCT00957229)
- Testing
- GDC-0449
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- UCSF Benioff Children's Hospital Oakland
Lung Non-Small Cell Carcinoma, Pleural Disorder
Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease
This phase I trial evaluates the side effects of intraoperative photodynamic therapy with porfimer sodium in enhancing the response to immunotherapy with an immune checkpoint inhibitor drug in patients with non-small cell lung…
- Trial name
- NCT04836429
- Testing
- Porfimer Sodium, Video-Assisted Thoracic Surgery, Photodynamic Therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Roswell Park Cancer Institute
Rheumatoid Arthritis
Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia
An observational study assessing the impact of anti-citrullinated antibody (ACPA) in rheumatoid arthritis (RA) participants who have received abatacept or tumour necrosis factor inhibitors (TNFi) from the Optimising Patient…
- Trial name
- NCT03663829
- Testing
- Non-Interventional
- Where
- Australia
- Volunteers
- 2,052 people
- Sponsor
- Bristol-Myers Squibb
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
This study is to determine the response to acalabrutinib in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Trial name
- NCT02337829
- Testing
- Acalabrutinib (Arm A), Acalabrutinib (Arm B)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Acerta Pharma BV
Lymphedema Arm, Lymphedema Due to Radiation
Effectiveness of a Therapeutic Exercise Program With Specific Upper Limb Exercises to Reduce Lymphedema and Neuropathy in Breast Cancer Patients: A Pre-post Study (LYNMA)
This study aims to evaluate the effectiveness of a therapeutic exercise program designed specifically for women with breast cancer.
- Conditions
- Lymphedema Arm, Lymphedema Due to Radiation, Lymphedema, Breast Cancer, Peripheral Neuropathy Due to Chemotherapy
- Trial name
- LYNMA (NCT07170631)
- Testing
- Therapeutic exercise
- Volunteers
- 30 people
- Sponsor
- Universitat Internacional de Catalunya
Infertility
Influence of a Prematuration Culture With a Phosphodiesterase-3 Inhibitor (PDE3-I) on Embryonic Aneuploidy Rate and Developmental Potential
A single centre randomised controlled trial investigating the influence of a novel prematuration system (PMS) using a phosphodiesterase-3 inhibitor for in-vitro maturation of oocytes
- Trial name
- NCT00823420
- Testing
- prematuration culture
- Where
- Belgium
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Prostate Cancer
Hyaluronic Acid for Hypofractionated Prostate Radiotherapy
The present Phase II study aims to assess the rates of late rectal toxicities of grade ≥ 2 after hypofractionated radiotherapy of prostate cancer of 62 Gy in 20 fractions of 3.1 Gy with an injection of hyaluronic acid (HA) in the…
- Trial name
- RPAH1 (NCT02165020)
- Testing
- Hyaluronic acid (Macrolane VRF 30®, Q-MED)
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Hospices Civils de Lyon
Biliary Tract Neoplasm
Study of Oxaliplatin, Irinotecan, and S-1 in Biliary Tract Cancer
This study will conduct a phase II study of triple combination with oxaliplatin, irinotecan, and S-1 as the first-line chemotherapy in patients with advanced biliary tract cancer.
- Trial name
- NCT02527824
- Testing
- Oxaliplatin, Irinotecan, S-1
- Where
- South Korea
- Volunteers
- 31 people
- Sponsor
- Hallym University Medical Center
Non-hodgkin Lymphoma,B Cell, Multiple Myeloma
CAR T-cell Therapy in Patients With Renal Dysfunction
This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.
- Conditions
- Non-hodgkin Lymphoma,B Cell, Multiple Myeloma, Acute Lymphoblastic Leukemia, Adult
- Trial name
- NCT05909059
- Testing
- Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Northside Hospital, Inc.
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+).
- Trial name
- FRIDA (NCT05546580)
- Testing
- Iadademstat, Gilteritinib Oral Tablet
- Where
- 13 sites in United States
- Volunteers
- 50 people
- Sponsor
- Oryzon Genomics S.A.
Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC)
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)").
- Conditions
- Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors
- Trial name
- BrILliance (NCT06413680)
- Testing
- REGN10597, Cemiplimab
- Where
- 11 sites in United States
- Volunteers
- 240 people
- Sponsor
- Regeneron Pharmaceuticals
Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
The primary objectives of this study are as follows: Phase 1 (sequential dose-escalation): to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent and to determine the recommended Phase 2 dose…
- Conditions
- Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer, HR+/HER2- Metastatic Breast Cancer, Metastatic Urothelial Cancer
- Trial name
- ASCENT-J02 (NCT05101096)
- Testing
- Sacituzumab Govitecan-hziy
- Where
- 36 sites in Japan
- Volunteers
- 135 people
- Sponsor
- Gilead Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.